Previous 10 | Next 10 |
Shares of beaten-down biotech Novavax (NASDAQ: NVAX) are under pressure yet again. The vaccine developer's shares were down by 3.3% on average trading volume as of 12:30 p.m. ET Tuesday. For the year, Novavax's stock has now lost a staggering 79% of its value, and on Tuesday...
Novavax ( NASDAQ: NVAX ) on Friday said the Swiss drug regulator had expanded its temporary approval of its COVID-19 vaccine for use in teenagers aged 12 through 17 and as a booster dose for adults aged 18 and older. The clearance came from the Swiss Agency for Therapeutic P...
Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older PR Newswire GAITHERSBURG, Md. , Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnolo...
Novavax ( NASDAQ: NVAX ) on Friday said the World Health Organization (WHO) had approved South Korean biotech SK bioscience as a maker and supplier of the active substance in its COVID-19 vaccine. SK bioscience currently makes drug substance and drug product of the vaccine, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology firm Vaxart (NASDAQ: VXRT ) traded all over the map on Thursday as the company released encouraging top-line data for the first of a two-part clinical study of its oral coronavirus vaccine. ...
An expert panel of the European Medicines Agency (EMA) recommended expanding the conditional marketing authorization granted for Novavax ( NASDAQ: NVAX ) COVID-19 vaccine to allow its use as a booster shot in adults, the company announced Thursday. EMA’s Committee f...
Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older PR Newswire Authorization could allow Nuvaxovid™ to be used as a booster regardless ...
We should spare a thought for poor Novavax (NASDAQ: NVAX) which, despite notable success with its coronavirus vaccine Nuvaxovid, has generally not received much love from investors. That dynamic was very much in evidence on Wednesday when market participants drove the vaccine specia...
The shares of Novavax ( NASDAQ: NVAX ) reached a new 52-week low on Wednesday after the FDA announced U.S. regulatory authorization for Omicron-adjusted booster vaccines developed by rival COVID-19 vaccine makers Pfizer ( PFE )/BioNTech ( BNTX ) and Moderna ( MRNA )....
Vaccine stocks scored big wins for many investors during the earlier stages of the pandemic. But so far this year, they've done just the opposite. Leaders Moderna (NASDAQ: MRNA) , Pfizer (NYSE: PFE) , and BioNTech (NASDAQ: BNTX) all have dropped by percentages in the...
News, Short Squeeze, Breakout and More Instantly...
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 5.74% on an annualized basis producing an average annual return of 18.97...
Novavax to Participate in 2024 Jefferies Global Healthcare Conference PR Newswire GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today annou...
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Wednesday. Shares of American Airlines Group Inc. (NA...